人工智能正加速美国就业市场降温，叠加AI公司寻求美国政府"担保"等误解，美股三大指数齐跌。 当地时间11月7日，纳斯达克指数下跌1.9%，标普500指数下跌1.12%，道琼斯工业平均指数下跌0.84%。个股方面特斯拉股价下跌超 3%，但随着特斯拉股东批准了首席执行官马斯克价值1万亿美元的薪酬协议，盘后股价一度有所回升。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | | DJI | 道琼斯工业平均 | 46912.30c | -398.70 | -0.84% | | IXIC | 纳斯达克指数 | 23053.99c | -445.81 | -1.90% | | SPX | 标普500 | 6720.32c | -75.97 -1.12% | | "AI担忧"加剧，三大指数集体收跌 美股大型科技股出现普跌，英伟达和特斯拉跌幅均超3%，英特尔、亚马逊、Meta跌超2%，微软跌超1%，奈飞、苹果股价也小幅下 跌。据了解，微软已经连续七个交易日股价下跌，创下了2022年以来最长连跌天数。 当地时间周四，OpenAI联合创始人兼CEO萨姆·奥尔特 ...

Market Performance - The three major U.S. stock indices closed lower, with the Dow Jones down 0.84% at 46,912.3 points, the S&P 500 down 1.12% at 6,720.32 points, and the Nasdaq down 1.9% at 23,053.99 points [1] - Major tech stocks fell, with Nvidia and Tesla dropping over 3%, Intel, Amazon, and Meta down over 2%, and Microsoft down over 1% [1] - Popular Chinese concept stocks showed mixed results, with Xiaoma Zhixing down over 8%, Zai Ding Pharmaceutical down over 6%, and NIO down over 1%, while XPeng Motors rose over 9% and Baidu up over 3% [1] European Market - European stock indices also closed lower, with Germany's DAX down 1.29% at 23,740.38 points, France's CAC40 down 1.36% at 7,964.77 points, and the UK's FTSE 100 down 0.42% at 9,735.78 points [1] Commodity Prices - International precious metal futures generally declined, with COMEX gold futures down 0.20% at $3,984.80 per ounce and COMEX silver futures down 0.37% at $47.85 per ounce [1] - U.S. oil futures fell slightly, with the main contract down 0.12% at $59.53 per barrel and Brent crude down 0.08% at $63.47 per barrel [1] Currency and Bond Markets - The U.S. dollar index decreased by 0.45% to 99.70, while the offshore RMB appreciated against the dollar by 104 basis points to 7.1209 [1] - U.S. Treasury yields collectively fell, with the 2-year yield down 7.20 basis points to 3.553% and the 10-year yield down 7.60 basis points to 4.083% [1] - European bond yields also declined, with the UK 10-year yield down 2.9 basis points to 4.432% and Germany's 10-year yield down 2.3 basis points to 2.648% [1]

Economic Data - In October, U.S. companies announced layoffs of 153,000, a month-on-month increase of 183.1%, marking the highest October figure since 2003 [3] - Year-to-date, total layoffs in the U.S. have reached 1.1 million, a year-on-year increase of 65%, the highest level since the pandemic [3] - International oil prices fell, with WTI crude futures at $59.43 per barrel, down 0.29%, and Brent crude at $63.38 per barrel, down 0.22% [3] - COMEX gold futures closed down 0.05% at $3,991.0 per ounce [3] Company Updates - Huahong Semiconductor reported record sales revenue in Q3, with a year-on-year increase of 20.7% [5] - BeiGene expects revenue for 2025 to be between 36.2 billion and 38.1 billion yuan [5] - Weichai Power plans to establish a production line for batteries and stacks aimed at the fixed power generation market, targeting AI data centers and similar applications [5] - ST Suwu may face forced delisting due to legal violations and has indicated multiple risks [5] - Qujiang Cultural Tourism's controlling shareholder's 4.06% stake is up for auction [5] Market Trends - Short-term market dynamics may accelerate due to a policy and earnings vacuum in November, according to Galaxy Securities [5] - Debon Securities suggests the market may maintain a combination of dividend, micro-market, and industrial trends in the short term [5] - According to招商证券, the overall liquidity in China is expected to remain relatively loose, with potential adjustments in the Fed's interest rate expectations, leading to a possible shift in market style from tech growth to a more balanced structure in November [5]

格隆汇11月7日｜美股三大指数收盘集体收跌，纳指跌1.9%，标普500指数跌1.12%，道指跌0.84%。大 型科技股普跌，英伟达、特斯拉跌超3%，英特尔、亚马逊、Meta跌超2%，微软跌超1%，奈飞、苹果 小幅下跌；谷歌小幅上涨。其中，微软连续七个交易日下跌，创2022年以来最长连跌天数。Robinhood 跌近11%，创3月份以来最差单日表现。多邻国跌超25%，创该公司美国IPO以来最差单日表现。 纳斯达克中国金龙指数跌0.03%，热门中概股涨跌不一，小马智行跌超8%，再鼎医药跌超6%，联电跌 超5%，金山云、名创优品跌逾3%，蔚来、霸王茶姬等跌超1%，携程网、腾讯音乐等小幅下跌；小鹏汽 车涨超9%，百度涨超3%，阿里巴巴、极氪涨超1%，BOSS直聘，理想汽车等小幅上涨。 ...

Major Events - Yuejiang (02432) plans to place 16.66 million shares at a discount of approximately 10.3%, raising about HKD 771 million [1] - Qingci Games (06633) has signed a game licensing transfer agreement with Disney [1] - Yaoshi Bang (09885) experiences stock price fluctuations and will repurchase shares up to a total of HKD 100 million [1] - China Qinfa (00866) has been included in the MSCI Global Small Cap Index [1] - China Tobacco Hong Kong (06055) signs an exclusive distribution agreement for "Crown" cigars in the global market with Anhui Tobacco [1] - Weichai Power (02338) signs a manufacturing license agreement with Hylis [1] Financial Reports - Galaxy Entertainment (00027) reports third-quarter net income of HKD 12.2 billion, a year-on-year increase of 14% [1] - BeiGene (06160) reports adjusted net profit of approximately USD 304 million for the third quarter, a year-on-year increase of 489% [1] - Hua Hong Semiconductor (01347) reports third-quarter profit attributable to shareholders of USD 25.725 million, a year-on-year decrease of 42.6% [1] - Autohome-S (02518) reports third-quarter net profit attributable to the parent of HKD 436.6 million, with online marketing and other business revenue increasing by 32.1% year-on-year [1] - Zai Lab (09688) reports total revenue growth of 14% year-on-year, reaching USD 116.1 million for the third quarter [1] - Yidu International Holdings (00259) issues a positive profit alert, expecting half-year profit attributable to shareholders of approximately HKD 1.2 billion, a year-on-year increase [1] - Tianli International Holdings (01773) issues a positive profit alert, expecting annual profit of approximately HKD 650 million, a year-on-year increase of about 17% [1] - Damai Entertainment (01060) expects mid-term net profit to increase to no less than HKD 500 million year-on-year [1] - Cafe de Coral Group (00341) issues a profit warning, expecting mid-term profit attributable to shareholders to decrease by 65% to 70% year-on-year [1] - China Overseas Development (00688) reports cumulative contract property sales of approximately HKD 189.165 billion for the first ten months, a year-on-year decrease of 21.3% [1]

Core Viewpoint - Zai Ding Pharma reported a 14% year-on-year increase in total revenue for Q3 2025, reaching $116.1 million, with a narrowed operating loss of $48.8 million, down 28% year-on-year, and an adjusted operating loss reduced by 42% to $28 million. The company has adjusted its full-year revenue guidance for 2025 to at least $460 million [1] Financial Performance - Total revenue for Q3 2025 was $116.1 million, a 14% increase compared to the previous year [1] - Product revenue net amounted to $115.4 million, up 13% from $101.8 million in the same period of 2024, with a 14% increase when adjusted for constant exchange rates [1] - The operating loss was $48.8 million, a reduction of 28% year-on-year, while the adjusted operating loss was $28 million, down 42% [1] Growth Drivers - The revenue growth was primarily driven by increased sales of Zocor and Dingyoule, partially offset by a slowdown in sales of Zele [1] - The company is entering a new growth phase, supported by its commercial capabilities in China and a robust pipeline of global projects [1] Future Outlook - The company is preparing for the upcoming launch of KarXT in the schizophrenia field, while continuing to strengthen the foundation for the launch of Aigamod in the myasthenia gravis area [1] - There is a steady increase in the number of new patients starting treatment and an extension in treatment duration for Aigamod, indicating growing confidence among doctors [1]

Core Insights - Zai Lab (09688) reported a 14% year-over-year increase in total revenue for Q3 2025, reaching $116.1 million, with operating losses narrowing by 28% to $48.8 million, and adjusted operating losses reduced by 42% to $28 million [1][1][1] - The company has adjusted its full-year revenue guidance for 2025 to at least $460 million [1] Revenue Breakdown - Product revenue netted $115.4 million, up 13% from $101.8 million in the same period of 2024, with a 14% increase when calculated at constant exchange rates (CER) [1][1] - Growth was primarily driven by increased sales of Zymeworks and Dingo, partially offset by a slowdown in sales of Zole [1] Management Commentary - The founder and CEO, Dr. Ying Du, stated that Zai Lab is entering a new growth phase, supported by a robust commercialization capability in China and a rapidly advancing global pipeline [1][1] - The company is advancing multiple differentiated global projects, showcasing the speed and scientific rigor of its R&D engine [1] - The President and COO, Josh Smiley, emphasized the strengthening foundation for the launch of Efgartigimod, with increasing new patient numbers and extended treatment durations in the myasthenia gravis field [1][1] - The company is preparing for the anticipated launch of KarXT in the schizophrenia space, while maintaining robust operations and positioning for significant future opportunities [1][1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號: 9688） 海外監管公告 – 表格 10-Q 本公告乃由再鼎醫藥有限公司（「本公司」）根據香港聯合交易所有限公司證券上 市規則第13.10B條而作出。 本公司於2025年11月6日向美國證券交易委員會（「SEC」）遞交了截至2025年9月 30日止季度的季度報告表格10-Q（「表格10-Q」）。詳情請參閱隨附表格10-Q，其 已於SEC網站www.sec.gov及本公司網站www.zailaboratory.com刊發。 承董事會命 再鼎醫藥有限公司 董事長兼首席執行官 杜瑩 Zai Lab Limited 再鼎醫藥有限公司* 香港，2025年11月6日 於本公告日期，本公司董事會包括董事杜瑩博士；以及獨立董事 John Diekman 博士、 Richard Gaynor 博士、梁頴宇女士、 William Lis 先生、 Scott W. Morri ...

Financial Performance - Total revenue for Q3 2025 increased by 14% year-over-year, reaching $116.1 million[6] - Operating loss for Q3 2025 was $48.8 million, a reduction of 28% compared to the previous year[6] - Adjusted operating loss narrowed by 42% to $28 million for Q3 2025[6] - In Q3 2025, product revenue net amounted to $115.4 million, a 13% increase year-over-year, driven by sales growth of Newzai and Dingyoule[11] - The net loss for Q3 2025 was $36 million, with a loss per share of $0.03, an improvement from a net loss of $41.7 million and a loss per share of $0.04 in the same period of 2024[11] - Total revenue for the three months ended September 30, 2025, was $116,095,000, representing a 13% increase compared to $102,265,000 in the same period of 2024[36] - Product revenue for the nine months ended September 30, 2025, reached $330,095,000, a 14% increase from $289,102,000 in the same period of 2024[38] - Operating loss for the three months ended September 30, 2025, was $(48,822,000), a 28% improvement compared to $(67,853,000) in the same period of 2024[39] - Net loss for the nine months ended September 30, 2025, was $(125,128,000), down from $(175,419,000) in the same period of 2024[37] - Adjusted operating loss for the three months ended September 30, 2025, was $(27,998,000), compared to $(48,187,000) in the same period of 2024[39] Guidance and Projections - The company has set a full-year revenue guidance of at least $460 million for 2025[6] - The company adjusted its full-year 2025 total revenue guidance to at least $460 million[22] - Future projections include expectations for revenue growth, profitability, and cash flow from commercialized products and clinical-stage candidates[31] Research and Development - Zocilurtatug Pelitecan (zoci) has shown a 68% overall response rate in the 1.6 mg/kg dose group for the treatment of extensive-stage small cell lung cancer[9] - The median duration of response (DoR) for patients in the same group is estimated at 6.1 months[9] - KarXT has been included in national treatment guidelines in China, highlighting the urgent need for new therapies in the schizophrenia field[6] - The company plans to submit a marketing authorization application for tumor treating fields therapy for pancreatic cancer in Q4 2025[9] - ZL-1503 (IL-13xIL-31R) has initiated a global Phase 1/1b study to evaluate its safety and pharmacokinetics[9] - The company is preparing for the anticipated launch of KarXT in the schizophrenia market[6] - KarXT was included in the "China Schizophrenia Prevention and Treatment Guidelines (2025 Edition)" as the first national-level guideline globally, highlighting its effectiveness in three symptom areas[11] - The company plans to submit a new drug clinical trial application for ZL-6201 for treating sarcoma patients in Q4 2025[15] - The company expects to announce key results from ongoing clinical studies in 2026, including updates on the efficacy of Zocilurtatug Pelitecan in treating various cancers[17] - The company is preparing to submit marketing authorization applications for several products, including a new treatment for first-line pancreatic cancer in Q4 2025[18] Financial Position - As of September 30, 2025, cash and cash equivalents totaled $81.72 million, down from $83.23 million as of June 30, 2025[12] - As of September 30, 2025, cash and cash equivalents increased to $717.155 million from $449.667 million as of December 31, 2024, representing a growth of approximately 59.7%[34] - Total assets decreased to $1.159 billion as of September 30, 2025, from $1.186 billion as of December 31, 2024, a decline of about 2.3%[34] - Current liabilities increased to $359.769 million as of September 30, 2025, compared to $299.385 million as of December 31, 2024, reflecting an increase of approximately 20.2%[34] - The company reported a total of $85.377 million in accounts receivable as of September 30, 2025, slightly up from $85.178 million as of December 31, 2024[34] - Inventory net increased to $67.135 million as of September 30, 2025, from $39.875 million as of December 31, 2024, indicating a rise of approximately 68.5%[34] - The company has a non-current restricted cash of $1.115 million as of September 30, 2025, consistent with $1.114 million as of December 31, 2024[34] - Total liabilities rose to $398.995 million as of September 30, 2025, compared to $344.855 million as of December 31, 2024, marking an increase of about 15.7%[34] - The total equity as of September 30, 2025, was $759,945,000, a decrease from $840,898,000 as of December 31, 2024[35] - The total liabilities and equity as of September 30, 2025, was $1,158,940,000, compared to $1,185,753,000 as of December 31, 2024[35] - The company reported a foreign currency translation adjustment loss of $(6,703,000) for the three months ended September 30, 2025[37] Operational Focus - The company emphasizes the importance of non-GAAP financial metrics for understanding operational performance and financial results[30] - The company is focused on addressing unmet medical needs in oncology, immunology, neuroscience, and infectious diseases through innovative product development[27]

公司名稱: 再鼎醫藥有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | | --- | | 2025年10月31日 | | 狀態: | | 新提交 | 致：香港交易及結算所有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09688 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.000006 | USD | | 30,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.000006 | ...